Loading clinical trials...

Resource Use and Disease Course in Dementia (REDIC) | Clinical Trials | Clareo Health

COMPLETED

Resource Use and Disease Course in Dementia (REDIC)

NCT01920100•Sykehuset Innlandet HF

Summary

This project is based on a three-year program that aims to improve the knowledge of the socioeconomic consequences of dementia in Norway. By including patients with and without dementia in four different cohorts (from nursing homes, from memory clinics, home-dwelling persons with dementia and elderly persons without dementia), the project's aim is to describe the course of dementia, the economical cost of dementia and to look into possible risk factors for dementia.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Memory clinic sample
•All patients examined at a memory clinic with mild cognitive impairment or mild dementia
•Persons 70 years of age or older receiving in-home care from the municipality
•All persons admitted to the nursing home with an expected stay of more than four weeks.
•Participants should be 65 years or older, unless established dementia disease, in which case younger persons also will be included
•Persons 65 years or older without any sign of dementia

Exclusion Criteria

•None
•In-home care sample
•None
•Nursing-home sample
•Life expectancy of less than six weeks
•Control sample
•None

Locations (3)

University of Bergen

Bergen, Norway

Senter for omsorgsforskning - Midt

Namsos, Norway

Innlandet Hospital Trust

Ottestad, Norway

Key Dates

Start Date

April 1, 2009

Primary Completion Date

January 1, 2015

Completion Date

November 1, 2023

Last Updated

November 24, 2023

Enrollment

696

ACTUAL participants

Conditions

Neurodegenerative DiseasesDementia

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGPHASE3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

Alzheimer DiseaseDementia+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 24, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Resource Use and Disease Course in Dementia (REDIC)

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Testing the Pain Clinical Practice Guideline

Circadian Rhythm and Other Factors in Memory Clinic Patients

Neurocognitive Assessment Platform 4 Alzheimer